JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
140.97
+0.59 (+0.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close140.38
Open141.25
Bid140.97 x 800
Ask141.30 x 1000
Day's Range140.33 - 141.84
52 Week Range109.16 - 157.00
Volume5,029,521
Avg. Volume8,440,855
Market Cap371.646B
Beta (5Y Monthly)0.70
PE Ratio (TTM)22.00
EPS (TTM)6.41
Earnings DateJul 16, 2020
Forward Dividend & Yield4.04 (2.88%)
Ex-Dividend DateMay 22, 2020
1y Target Est164.24
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-8% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Johnson & Johnson Gets European Approval for Ebola Vaccine
    Zacks

    Johnson & Johnson Gets European Approval for Ebola Vaccine

    J&J (JNJ) gets approval from the European Commission for Ebola vaccine.

  • Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses
    Reuters

    Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

    Early signs of the shift came Wednesday, when positive data for one of Pfizer Inc’s COVID-19 vaccine candidates sent shares of the large U.S. drugmaker up more than 3%. Although the news had little effect on shares of Pfizer’s large rivals in the vaccine race, smaller peers Moderna Inc and Inovio Pharmaceuticals Inc, both of which have previously shown promising COVID-19 data of their own, ended down more than 4% and 25%, respectively. For the week so far, shares of bigger players in the vaccine race, such as Johnson & Johnson and Merck , have also outperformed Inovio and Moderna.

  • Were Hedge Funds Right About Cutting Johnson & Johnson (JNJ)?
    Insider Monkey

    Were Hedge Funds Right About Cutting Johnson & Johnson (JNJ)?

    We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]

  • Barrons.com

    The Number of Covid-19 Cases Is Rising. What Comes Next.

    The coronavirus pandemic is worsening in the U.S. as the second half of the year gets under way. This past Wednesday, more than 50,000 new cases were identified across the country, according to a Johns Hopkins University tracking tool, a record. More than 35,000 new cases have been identified in the U.S. each day since June 25.

  • Will Legal Problems Bankrupt Johnson & Johnson?
    Motley Fool

    Will Legal Problems Bankrupt Johnson & Johnson?

    A flurry of legal challenges is always a good reason for investors to be wary of a company. Lawsuits related to its talc-based products and the company's role in the opioid crisis present some of the biggest risks to long-term investors. Although J&J may be able to manage those legal challenges today, that doesn't mean it always will.

  • Pedal to the Metal Leads to Record Rebound
    GuruFocus.com

    Pedal to the Metal Leads to Record Rebound

    Like a race car pushing the pedal to the metal, the stock market sped to its best quarterly stock market gains in decades Continue reading...

  • Barrons.com

    New FDA Guidance May Not Allow Covid-19 Vaccine This Year, Analyst Says

    The Food and Drug Administration’s new guidance document for developers of Covid-19 vaccines doesn’t spell out a timeline. SVB Leerink analyst Geoffrey Porges says the guidelines point firmly toward no vaccine being made available until next year.

  • Better Buy: Eli Lilly vs. Johnson & Johnson
    Motley Fool

    Better Buy: Eli Lilly vs. Johnson & Johnson

    As two of the largest healthcare companies in the world, both Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) have a role to play in well-balanced healthcare portfolios. With a profit margin of 23.8%, 15.1% year-over-year quarterly revenue growth, and trailing-12-month revenues of $23.1 billion, Eli Lilly exudes success.

  • This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines
    Motley Fool

    This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines

    Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.

  • Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed
    MarketWatch

    Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed

    Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.

  • J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus
    Zacks

    J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus

    Johnson & Johnson (JNJ) discontinues phase III study of Stelara (ustekinumab) in systemic lupus erythematosus.

  • J&J scraps late-stage study testing Stelara for lupus
    Reuters

    J&J scraps late-stage study testing Stelara for lupus

    Stelara, which blocks two inflammation-causing proteins IL-12 and IL-23, is one of J&J's largest revenue generators, bringing in sales of about $1.82 billion in first quarter this year. The drug is approved in the United States to treat the skin condition scaly plaque psoriasis, a type of arthritis associated with psoriasis and Crohn's disease.

  • Barrons.com

    Regeneron Used a Charity to Pay Kickbacks, Justice Department Alleges

    Regeneron hiked the price of its drug Eylea and spurred its sales by using a charitable foundation to cover Medicare patients’ out-of-pocket costs for the pricey drug, according to a civil suit.

  • Bayer Isn’t Out of the Roundup Woods as 30,000 Claims Remain
    Bloomberg

    Bayer Isn’t Out of the Roundup Woods as 30,000 Claims Remain

    (Bloomberg) -- While Bayer AG said it took a major step toward wrapping up litigation over its Roundup weedkiller with a settlement of almost $11 billion, the company still faces about 30,000 unresolved cancer claims that could cost billions, and lawyers are vowing even more lawsuits.“If Bayer and its investors thought the Roundup litigation was wrapped up in a nice, neat ball with this settlement, they are sadly mistaken,” said Tom Kline, a Philadelphia-based plaintiffs’ lawyer who won an $8 billion verdict against Johnson & Johnson last year over one of its anti-psychotic drugs. “We are working hard getting these cases in and ready for trial.”Roundup litigation was by far the biggest liability that the German chemical giant inherited when it acquired Monsanto for $63 billion in 2018. On Wednesday, Bayer announced settlements totaling $12.1 billion that included as much as $10.9 billion for Roundup, $820 million for toxic-chemical pollution and $400 million related to damage from a dicamba-based herbicide.But Bayer only managed agreements to end about 95,000 of the 125,000 lawsuits claiming Roundup caused cancer. The others refused to settle, and the number of cases is growing. Last week, attorney Fletch Trammell filed 13 suits on behalf of kids who developed non-Hodgkin’s lymphoma after being exposed to the weedkiller in backyards, parks and playgrounds.Read More: How Roundup Went From Bayer Asset to Burden“The settlement announcement feels like Bayer is trying to stop a gigantic problem by putting its finger in the proverbial dam,” said Jason Itkin, a Houston based lawyer who won a $70 million verdict against J&J last year. “Every day, new people are diagnosed with Roundup-induced cancer. There will be thousands and thousands of future cases because Bayer is currently still selling this dangerous product.”The company denies Roundup’s active ingredient, glyphosate, is a carcinogen, a position backed by the U.S. Environmental Protection Agency.William Dodero, Bayer’s global head of litigation, said at a press conference Wednesday he couldn’t predict how many new Roundup cases will emerge. But the Leverkusen, Germany-based company has made progress in ending its Roundup litigation, resolving all the cases set for trial and those brought by the plaintiffs’ lawyers leading the litigation, Dodero said.The settlements must still be approved by a federal judge in San Francisco who has some of the cases consolidated before him.“This litigation has been going on for four years with speculation about settlement for more than a year and plaintiff attorneys have had ample opportunity to bring forward claims,” Chris Loder, a company spokesman, said in an emailed statement. “We’ve now settled approximately 75% of claims, resolved cases with all leaders” on the plaintiffs side and “have an allowance to resolve the remaining cases.”Shareholders seemed to welcome the agreements. Bayer’s American depositary receipts climbed on the settlement news, gaining as much as as 5%. The ADRs, which represent one-quarter of a regular share, were up 15 cents to $20.54 at 5:19 p.m. in New York.The company made offers to all the holdouts and is “confident that we can bring this to a final closure in due course,” Dodero said.Too LowBut Bayer’s settlement offers were insultingly low, according to James Onder, a St. Louis lawyer who held his 24,000 cases out of the settlement.“The unsettled legal exposure for Bayer could easily exceed tens of billions of dollars as our firms and others have rejected the minuscule offers accepted by some other lawyers,” Onder said in an email. “To act as if one quarter of the Roundup cancer victims don’t exist is nothing more than a flagrant attempt by Bayer to manipulate its stock price and serves as a slap in the face” to those victims, he said.After Bayer officials refused to make “serious” settlement offers, Trammell said he filed the 13 state court cases on behalf of families who say their children developed non-Hodgkin’s lymphoma from Roundup exposure. Eleven suits were filed in St. Louis last week and the others were file in San Francisco, he said.The children range in age from five to 17, according to court filings. Most are still battling their cancers, but 13-year-old Jacob Savage of Forks, Washington, died in 2017. Bayer has been hit with at least 20 other suits involving children and Roundup, court dockets show.“I’m happy they didn’t settle with me and that I can go out and get more good cases,” said Mark Robinson, a California attorney. “These guys need a couple of more verdicts against them to start valuing the cases properly.”The company lost three damage verdicts totaling more than $191 million. While those cases are on appeal, they spurred a surge in new filings over the past year that led to a plunge in Bayer shares.Precautions taken by courts during the Covid-19 pandemic -- including suspensions of jury selection -- may make it difficult for any of the plaintiff laywers to get cases set for trial until at least next year, said Ken Feinberg, who is serving as the chief settlement mediator in the Roundup cases.“I predict all the remaining cases will settle within a few months,” Feinberg said. “People are going to want their share of this settlement.”Glenn Norton, a retired Missouri appellate judge who served as a mediator for cases in St. Louis and worked with Feinberg on national settlements, said lawyers whose cases weren’t part of Wednesday’s agreement are still “determined to get them settled, too.”Norton said “Bayer paid a little more than people thought they would” to resolve most of the Roundup cases, which shows company officials were keen to get as much of the litigation behind them as possible.The consolidated case is In re: Roundup Products Liability Litigation, MDL 2741, U.S. District Court, Northern District of California (San Francisco).(Updates comment from mediator Norton. An earlier version of this story corrected a comment by the chief mediator, Feinberg.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Barrons.com

    Moderna Is the Latest Coronavirus Vaccine Partner for Catalent

    The biotech company Moderna said it has teamed up with Catalent to make the Covid-19 vaccine that it is about to test in the country’s first large clinical trial.

  • Vaccine makers face biggest medical manufacturing challenge in history
    Reuters

    Vaccine makers face biggest medical manufacturing challenge in history

    From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.

  • Reuters

    INSIGHT-Vaccine makers face biggest medical manufacturing challenge in history

    From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.

  • Reuters

    Unilever, rivals mull changes amid global backlash against skin-lightening products

    Unilever is considering marketing changes to its dominant line of skin lightening creams, according to a company source in South Asia, even as the company and its rivals face a growing global social media backlash against such products. Products marketed as skin lightening have a huge market in South Asia, due to a societal obsession with fairer skin tones. Unilever's 'Fair & Lovely' brand dominates the market in South Asia, while similar products are sold by L'Oréal and Procter & Gamble.

  • Johnson & Johnson Option Trader Makes $1.7M Bet On 17% Upside
    Benzinga

    Johnson & Johnson Option Trader Makes $1.7M Bet On 17% Upside

    Johnson & Johnson (NYSE: JNJ) shares are up 36.1% in the last three months amid a broad market recovery. While the near-term economic outlook is unclear given COVID-19 uncertainty, one large option trader made a big bet Wednesday that Johnson & Johnson shares are headed much higher in the long run. The Johnson & Johnson Trade On Wednesday morning, Benzinga Pro subscribers received an option alert related to an unusually large Johnson & Johnson trade: * At 10:18 a.m., a trader bought 1,800 Johnson & Johnson call options with a $155 strike price expiring in June 2022 at the ask price of $9.60. The trade represented a more than $1.72-million bullish bet.Why It's Important Even traders who stick exclusively to stocks often monitor option market activity closely for unusually large trades. Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader.Many of these large options traders are wealthy individuals or institutions who may have unique information or theses related to the underlying stock.Unfortunately, stock traders often use the options market to hedge against their larger stock positions, and there's no surefire way to determine if an options trade is a standalone position or a hedge. In this case, given the relatively large size of Wednesday's Johnson & Johnson option trade, it could certainly be institutional hedging.Johnson & Johnson's Guidance Update On Wednesday, the Missouri Court of Appeals reduced Johnson & Johnson's damages related to a lawsuit linking the company's talc powder to cancer in 22 women from $4.69 billion to $2.12 billion.The stock didn't react much to the ruling given that Johnson & Johnson still faces significant legal liability in other cases related to the talc powder and the opioid epidemic.Johnson & Johnson also provided a general guidance update this week in a conference call with BofA Securities analyst Bob Hopkins.In the call, CFO Joe Wolk said Johnson & Johnson's medical device sales are tracking to be down nearly 50% in April and May. The company is confident it will outpace peer growth in its consumer and pharma businesses in 2020.Wolk also said the company is planning to appeal this week's Missouri ruling all the way to the state Supreme Court. Johnson & Johnson also said it is anticipating an opioid settlement potentially by the end of the year.Finally, management said it is expecting to begin testing a potential COVID-19 vaccine in human subjects by the end of July. JNJ Chart by TradingView new TradingView.widget( { "width": 680, "height": 423, "symbol": "NYSE:JNJ", "interval": "D", "timezone": "Etc/UTC", "theme": "light", "style": "1", "locale": "en", "toolbar_bg": "f1f3f6", "enable_publishing": false, "allow_symbol_change": true, "container_id": "tradingview_8a4e6" } ); Benzinga's Take Wednesday's large option trader may be betting that Johnson & Johnson will ultimately win the race to bring a coronavirus vaccine to market, or the trader may simply be betting that concerns over talc powder and opioid litigation are overblown.The June 2022 calls have a break-even price of $164.60, suggesting at least 17.4% upside from current levels.Do you agree with this take? Email feedback@benzinga.com with your thoughts.Related Links:Union Pacific Option Trader Makes .2M Bet On 5% Downside How To Read And Trade An Option AlertPhoto by Mattman723 via Wikimedia. See more from Benzinga * Analyst: S&P 500 'Likely To End 2020 At Or Close To Current Levels' * Tesla Analyst Gordon Johnson: 'I Couldn't Be More Bearish' * Canopy Growth Analyst Sees Increasing Cannabis Market Share, Little Stock Upside(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
    Zacks

    Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict

    J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

  • Johnson & Johnson Damages Halved To $2.12B By Court In Missouri But Verdict Stands
    Benzinga

    Johnson & Johnson Damages Halved To $2.12B By Court In Missouri But Verdict Stands

    An appeals court in Missouri has lowered the damages awarded to women who claimed that Johnson & Johnson's (NYSE: JNJ) baby powder caused their cancer diagnosis to $2.12 billion.What Happened Johnson & Johnson's attempt at overturning the verdict in favor of 22 women and their families did not succeed at the Missouri Court of Appeals on Tuesday, but damages against the company were lowered from $4.69 billion, reported Reuters.The court held that Johnson & Johnson and an affiliate had "worked tirelessly" to make sure that asbestos could not be detected in talc samples and also published articles that diminished the dangers posed by talc.Calling Johnson & Johnson's conduct outrageous, the court said, "there was significant reprehensibility in defendants' conduct."Johnson & Johnson plans to appeal to the Missouri Supreme Court. A company spokesperson said, "We continue to believe this was a fundamentally flawed trial, grounded in a faulty presentation of the facts."Why It Matters Reuter's breakdown of damages shows that Johnson & Johnson will have to pay $500 million of compensatory damages and $1.62 billion of punitive damages. The figures are significantly lower than $550 million in compensatory damages and $4.14 punitive damages imposed by a Missouri circuit court.An investigation by Reuters in 2018 showed that Johnson & Johnson knew for decades that its talc was tainted with asbestos.The company has discontinued the sale of its baby powder in the United States and Canada, as demand declines and it faces thousands of lawsuits. Price Action On Tuesday, Johnson and Johnson's shares closed 0.37% lower at $142.86.See more from Benzinga * Alphabet Employee Petition Calls For Google To Stop Selling Services To The Police * Trump Says China Trade Deal 'Fully Intact' After Mixed Messages From Navarro * Fastly Continues Surge As Work-From-Home Trend Continues(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Reuters

    PRESS DIGEST- New York Times business news - June 24

    - TaskRabbit chief executive Stacy Brown-Philpot, one of the few prominent black women in Silicon Valley, is stepping down after four years running the San Francisco-based marketplace for gig workers. - A Missouri appeals court on Tuesday ordered Johnson & Johnsonc and a subsidiary to pay $2.1 billion in damages to women who blamed their ovarian cancers on the company's talcum products, including its iconic baby powder.